Creative Medical files new US provisional patent to expand Ultrasome cell-free platform protection
CELZ•Pilot study results and platform background
The Ultrasome pilot knee osteoarthritis study reported about 93% of participants had clinically meaningful mobility and pain improvements, with no serious adverse events.
The platform is derived from the Olastrocel regenerative program, using a GMP master cell bank supported by an FDA Drug Master File.
Provisional patent filing expands Ultrasome IP
Creative Medical Technology Holdings filed a new U.S. provisional patent application to expand IP protection for its Ultrasome cell-free regenerative platform.
The application targets product composition, potency testing, manufacturing controls, stability and delivery methods, broadening development beyond the initial knee osteoarthritis program.
